Global buyout fund KKR is planning to acquire a third of Hyderabad based, Gland Pharma for a consideration of R1000 Cr valuing the company at $500 million (R3,000-3,500 Cr), ET states. The deal would provide the pharma company with fresh equity as well as an exit to its existing investor, Evolvance India Life Science Fund. The funds received to the tune of R600-700 Cr would be utilized for augmenting the manufacturing capacity of the firm and the balance would provide an exit route to EIF.
Help employers find you! Check out all the jobs and post your resume.
